Amgen Inc is projected to report Q3 2026 revenue of $9.68 billion and EPS of $5.74, while the current stock price of $315.42 remains below the $345.20 average analyst target. Investors are primarily focused on the clinical progression and Phase 3 trial enrollment of MariTide, the company's high-stakes entry into the competitive obesity market.
Recent growth has been driven by the successful integration of Horizon Therapeutics, with strong contributions from rare-disease assets like Tepezza and Krystexxa. Market participants will scrutinize management's updated 2026 guidance and commentary regarding the competitive landscape for metabolic therapies.